Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$1.45
-$0.09(-4.55%)
At close: 4:00 PM EST
$1.45
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.66M
Market Cap
$158.27M
Enterprise Value$50.46M
Total Cash (Recent Filing)$291.11M
Total Debt (Recent Filing)$37.88M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
Mar 03, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,151,474
10 Day Avg. Volume1,846,599
30 Day Avg. Volume1,658,891
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.44
Price to Sales (P/S)1.82
P/FCF Ratio-0.79
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$2.06Price Target Upside42.07% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)-1.43
Revenue Forecast (FY)$16.82M
Bulls Say, Bears Say
Bulls Say
Long-term Financial StabilityThe company has a cash runway through 2027, providing financial stability for its future operations.
Platform DifferentiationAlector's ABC platform now becomes the central long term value driver, with its differentiated transferrin receptor binding and tunability demonstrating significant brain uptake and favorable safety signals.
Strategic OpportunityThe ABC platform offers a broader, more strategic opportunity, enabling delivery of antibodies, enzymes, and siRNA into the CNS, increasingly valued by pharma.
Bears Say
Clinical UncertaintyThe Ph3 INFRONT-3 miss leaves uncertainty about the clinical value of PGRN elevation.
Program FailureThe failure of latozinemab to translate elevated PGRN levels into clinical efficacy suggests doubts about its effectiveness and the viability of SORT1 as a target.
Workforce ReductionA significant reduction in workforce by 47% and narrowing of the pipeline has been reported, indicating operational challenges.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $158.27M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Mar 03, 2026 which is in 69 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Nov 06, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.408 by $0.068.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.39.
How many shares outstanding does Alector Inc have?
Alector Inc has 109,151,474 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.408. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.06 (42.07% Upside)
$2.06 (42.07% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 158.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.04%
12-Months-Change
Fundamentals
Return on Equity
-121.98%
Trailing 12-Months
Asset Growth
-35.03%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.View all ALEC earnings summariesALEC Stock 12 Month Forecast
Average Price Target
$2.06
▲(42.07% Upside)
Technical Analysis
AC Immune SA
―
I-MAB
―
Foghorn Therapeutics
―
Vor Biopharma
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---